Bank of Hawaii Takes $495,000 Position in Glaukos Corporation $GKOS

Key Points

• Bank of Hawaii has made a new investment of approximately $495,000 in Glaukos Corporation, acquiring 5,026 shares of the medical instruments supplier's stock.
• The stock's current market cap is $5.26 billion, and it has recently experienced a 2.5% decline, with shares opening at $91.78.
• Research analysts generally hold a positive view on Glaukos, with an average rating of "Moderate Buy" and a price target around $127.42.

Bank of Hawaii acquired a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,026 shares of the medical instruments supplier's stock, valued at approximately $495,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GKOS. Nuveen LLC purchased a new position in Glaukos in the first quarter worth about $31,474,000. Westfield Capital Management Co. LP grew its position in Glaukos by 34.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier's stock worth $106,705,000 after acquiring an additional 277,033 shares in the last quarter. Comerica Bank grew its position in Glaukos by 664.5% in the fourth quarter. Comerica Bank now owns 151,538 shares of the medical instruments supplier's stock worth $22,722,000 after acquiring an additional 131,715 shares in the last quarter. Wellington Management Group LLP grew its position in Glaukos by 6.1% in the first quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier's stock worth $225,460,000 after acquiring an additional 131,251 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Glaukos by 5,912.8% in the first quarter. GAMMA Investing LLC now owns 133,064 shares of the medical instruments supplier's stock worth $13,096,000 after acquiring an additional 130,851 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Trading Down 0.7%

Shares of NYSE:GKOS traded down $0.70 during trading hours on Friday, hitting $95.86. 488,453 shares of the company's stock traded hands, compared to its average volume of 846,228. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The business has a fifty day moving average price of $95.62 and a 200-day moving average price of $99.17. The firm has a market capitalization of $5.50 billion, a P/E ratio of -58.10 and a beta of 0.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same quarter in the previous year, the business earned ($0.52) earnings per share. The company's revenue for the quarter was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on GKOS. BTIG Research reiterated a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. Morgan Stanley dropped their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. William Blair upgraded Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Zacks Research lowered Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. Finally, UBS Group boosted their target price on Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and a consensus price target of $127.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.